Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2-Adrenergic Receptor Autoantibodies-An Interim Report

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Oct 14

PMID 37835071

Authors

Elisa Stein

Cornelia Heindrich

Kirsten Wittke

Claudia Kedor

Laura Kim

Helma Freitag

Anne Kruger

Markus Tolle

Carmen Scheibenbogen

Affiliations

Soon will be listed here.

Abstract

There is increasing evidence for an autoimmune aetiology in post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). SARS-CoV-2 has now become the main trigger for ME/CFS. We have already conducted two small proof-of-concept studies on IgG depletion by immunoadsorption (IA) in post-infectious ME/CFS, which showed efficacy in most patients. This observational study aims to evaluate the efficacy of IA in patients with post-COVID-19 ME/CFS. The primary objective was to assess the improvement in functional ability. Due to the urgency of finding therapies for post-COVID-Syndrome (PCS), we report here the interim results of the first ten patients, with seven responders defined by an increase of between 10 and 35 points in the Short-Form 36 Physical Function (SF36-PF) at week four after IA. The results of this observational study will provide the basis for patient selection for a randomised controlled trial (RCT), including sham apheresis, and for an RCT combining IA with B-cell depletion therapy. Trial registration number: NCT05629988.

Citing Articles

Cognitive Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Aetiology and Potential Treatments.

Bansal A, Seton K, Brooks J, Carding S Int J Mol Sci. 2025; 26(5).

PMID: 40076522 PMC: 11899462. DOI: 10.3390/ijms26051896.

Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study.

Stein E, Heindrich C, Wittke K, Kedor C, Rust R, Freitag H Lancet Reg Health Eur. 2025; 49:101161.

PMID: 39759581 PMC: 11699797. DOI: 10.1016/j.lanepe.2024.101161.

Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence.

Scheibenbogen C, Wirth K J Cachexia Sarcopenia Muscle. 2024; 16(1):e13669.

PMID: 39727052 PMC: 11671797. DOI: 10.1002/jcsm.13669.

Overlapping conditions in Long COVID at a multisite academic center.

Grach S, Dudenkov D, Pollack B, Fairweather D, Aakre C, Munipalli B Front Neurol. 2024; 15:1482917.

PMID: 39524912 PMC: 11543549. DOI: 10.3389/fneur.2024.1482917.

Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives.

Seton K, Espejo-Oltra J, Gimenez-Orenga K, Haagmans R, Ramadan D, Mehlsen J J Clin Med. 2024; 13(2).

PMID: 38256459 PMC: 10816159. DOI: 10.3390/jcm13020325.

References

Dotan A, David P, Arnheim D, Shoenfeld Y . The autonomic aspects of the post-COVID19 syndrome. Autoimmun Rev. 2022; 21(5):103071. PMC: 8848724. DOI: 10.1016/j.autrev.2022.103071. View

Freitag H, Szklarski M, Lorenz S, Sotzny F, Bauer S, Philippe A . Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J Clin Med. 2021; 10(16). PMC: 8397061. DOI: 10.3390/jcm10163675. View

Hartwig J, Sotzny F, Bauer S, Heidecke H, Riemekasten G, Dragun D . IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS. Brain Behav Immun Health. 2021; 3:100047. PMC: 8474590. DOI: 10.1016/j.bbih.2020.100047. View

Deumer U, Varesi A, Floris V, Savioli G, Mantovani E, Lopez-Carrasco P . Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview. J Clin Med. 2021; 10(20). PMC: 8538807. DOI: 10.3390/jcm10204786. View

Legler F, Meyer-Arndt L, Modl L, Kedor C, Freitag H, Stein E . Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort. EClinicalMedicine. 2023; 63:102146. PMC: 10469383. DOI: 10.1016/j.eclinm.2023.102146. View

Joseph P, Singh I, Oliveira R, Capone C, Mullen M, Cook D . Exercise Pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Postacute Sequelae of SARS-CoV-2: More in Common Than Not?. Chest. 2023; 164(3):717-726. PMC: 10088277. DOI: 10.1016/j.chest.2023.03.049. View

Riemekasten G, Petersen F, Heidecke H . What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases. Front Immunol. 2021; 11:564526. PMC: 7770155. DOI: 10.3389/fimmu.2020.564526. View

Sotzny F, Filgueiras I, Kedor C, Freitag H, Wittke K, Bauer S . Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022; 13:981532. PMC: 9552223. DOI: 10.3389/fimmu.2022.981532. View

Cotler J, Holtzman C, Dudun C, Jason L . A Brief Questionnaire to Assess Post-Exertional Malaise. Diagnostics (Basel). 2018; 8(3). PMC: 6165517. DOI: 10.3390/diagnostics8030066. View

10.

Vassiliou A, Vrettou C, Keskinidou C, Dimopoulou I, Kotanidou A, Orfanos S . Endotheliopathy in Acute COVID-19 and Long COVID. Int J Mol Sci. 2023; 24(9). PMC: 10179170. DOI: 10.3390/ijms24098237. View

11.

Merad M, Blish C, Sallusto F, Iwasaki A . The immunology and immunopathology of COVID-19. Science. 2022; 375(6585):1122-1127. DOI: 10.1126/science.abm8108. View

12.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

13.

Davis H, McCorkell L, Vogel J, Topol E . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21(3):133-146. PMC: 9839201. DOI: 10.1038/s41579-022-00846-2. View

14.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

15.

Gravelsina S, Vilmane A, Svirskis S, Rasa-Dzelzkaleja S, Nora-Krukle Z, Vecvagare K . Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. 2022; 13:928945. PMC: 9589447. DOI: 10.3389/fimmu.2022.928945. View

16.

Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M . Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS One. 2018; 13(3):e0193672. PMC: 5854315. DOI: 10.1371/journal.pone.0193672. View

17.

Wang E, Mao T, Klein J, Dai Y, Huck J, Jaycox J . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595(7866):283-288. DOI: 10.1038/s41586-021-03631-y. View

18.

Anaya J, Herran M, Beltran S, Rojas M . Is post-COVID syndrome an autoimmune disease?. Expert Rev Clin Immunol. 2022; 18(7):653-666. DOI: 10.1080/1744666X.2022.2085561. View

19.

Premraj L, Kannapadi N, Briggs J, Seal S, Battaglini D, Fanning J . Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J Neurol Sci. 2022; 434:120162. PMC: 8798975. DOI: 10.1016/j.jns.2022.120162. View

20.

Sukocheva O, Maksoud R, Beeraka N, Madhunapantula S, Sinelnikov M, Nikolenko V . Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J Adv Res. 2022; 40:179-196. PMC: 8619886. DOI: 10.1016/j.jare.2021.11.013. View